Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P12081: Variant p.Tyr330Cys

Histidine--tRNA ligase, cytoplasmic
Gene: HARS1
Feedback?
Variant information Variant position: help 330 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Tyrosine (Y) to Cysteine (C) at position 330 (Y330C, p.Tyr330Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and aromatic (Y) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In CMT2W; fails to complement deletion of the yeast ortholog; decreases histidine-tRNA ligase activity; increases in the KM for ATP binding; does not disrupt dimerization. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 330 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 509 The length of the canonical sequence.
Location on the sequence: help TLFGIDDKISFDLSLARGLD Y YTGVIYEAVLLQTPAQAGEE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         TLFGIDDKISFDLSLARGLDYYTGVIYEAVLLQ--------TPAQAGEE

Mouse                         ILFGIDDKISFDLSLARGLDYYTGVIYEAVLLQ--------

Bovine                        TLFGIADKISFDLSLARGLDYYTGVIYEAVLLQ--------

Zebrafish                     ELFQITDKVVFDLSLARGLDYYTGVIYEAILTQANPAPAST

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 509 Histidine--tRNA ligase, cytoplasmic
Binding site 326 – 326
Binding site 330 – 331
Turn 328 – 330



Literature citations
Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy.
Abbott J.A.; Meyer-Schuman R.; Lupo V.; Feely S.; Mademan I.; Oprescu S.N.; Griffin L.B.; Alberti M.A.; Casasnovas C.; Aharoni S.; Basel-Vanagaite L.; Zuechner S.; De Jonghe P.; Baets J.; Shy M.E.; Espinos C.; Demeler B.; Antonellis A.; Francklyn C.;
Hum. Mutat. 39:415-432(2018)
Cited for: VARIANTS CMT2W GLY-155; CYS-330 AND ASN-356; CHARACTERIZATION OF VARIANTS CMT2W GLY-155; CYS-330 AND ASN-356; CATALYTIC ACTIVITY; FUNCTION; BIOPHYSICOCHEMICAL PROPERTIES; SUBUNIT;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.